FDA vs. EMA Drug Approval Pathways

What's inside this guide

Global drug development often assumes the FDA and the European Medicines Agency are comparable regulators with interchangeable expectations. They are not. This 65-page, 15-chapter guide breaks down how each system actually behaves in practice, so you can design regulatory strategies that work on both sides of the Atlantic.

• Legal foundations and institutional architecture: why FDA and EMA make decisions so differently
• NDA, BLA and MAA: how the core marketing applications really differ
• The Common Technical Document (CTD): what it harmonizes — and what it does not
• PDUFA vs. EU fees: regulatory economics for global development
• Review clocks and clock stops: how regulatory time actually works
• Expedited pathways: Fast Track, Breakthrough Therapy and Priority Review vs. PRIME and Conditional Marketing Authorization
• Orphan drug designation: US vs. EU incentives and exclusivity
• Post-approval changes, pharmacovigilance (PADERs, PSURs/PBRERs) and labeling differences
• How to design a coherent global regulatory strategy from development to market

A practical reference for regulatory affairs professionals, clinical research managers, and anyone developing medicines for both US and EU markets.